

Central Lancashire Online Knowledge (CLoK)

Title	Distinguishing active from quiescent disease in ANCA-associated vasculitis using attenuated total reflection Fourier-transform infrared spectroscopy
Туре	Article
URL	https://clok.uclan.ac.uk/37758/
DOI	https://doi.org/10.1038/s41598-021-89344-8
Date	2021
Citation	Morris, Adam D., Medeiros-De-morais, Camilo De lelis orcid iconORCID: 0000-0003-2573-787X, Lima, Kássio M. G., Freitas, Daniel L. D., Brady, Mark E., Dhaygude, Ajay P., Rowbottom, Anthony and Martin, Francis L. (2021) Distinguishing active from quiescent disease in ANCA-associated vasculitis using attenuated total reflection Fourier-transform infrared spectroscopy. Scientific Reports, 11 (1). p. 9981.
Creators	Morris, Adam D., Medeiros-De-morais, Camilo De Ielis, Lima, Kássio M. G., Freitas, Daniel L. D., Brady, Mark E., Dhaygude, Ajay P., Rowbottom, Anthony and Martin, Francis L.

It is advisable to refer to the publisher's version if you intend to cite from the work. https://doi.org/10.1038/s41598-021-89344-8

For information about Research at UCLan please go to http://www.uclan.ac.uk/research/

All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the <u>http://clok.uclan.ac.uk/policies/</u>

Supplementary Information

Distinguishing active from quiescent disease in ANCA-associated vasculitis using attenuated total reflection Fourier-transform infrared spectroscopy

Adam D. Morris¹*, Camilo L. M. Morais², Kássio M. G. Lima³, Daniel L. D. Freitas³, Mark E. Brady¹, Ajay P. Dhaygude¹, Anthony W. Rowbottom^{4, 5}, Francis L. Martin⁶*

¹Renal Medicine, Royal Preston Hospital, Preston, UK

²School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, UK

³Institute of Chemistry, Biological Chemistry and Chemometrics, Federal University of Rio Grande do Norte, Natal, Brazil

⁴Department of Immunology, Royal Preston Hospital, Preston, UK

⁵School of Medicine, University of Central Lancashire, Preston, UK

⁶Biocel Ltd, Hull HU10 7TS, UK

No of Pages = 15 Number of Figures = 15 Number of Tables = 14



Figure S1: ANCA-associated **vasculitis participant flow -** AAV: ANCA-associated vasculitis, ***** Test set – samples used for blind predictive modelling for external validation of the classification systems performance, ******Training set – samples used for model construction of classification system



Figure S2: ATR-FTIR spectral classification of healthy controls (HC) vs. active disease (AD) & healthy controls (HC) vs. disease remission (DR) for plasma samples – (A) Average pre-processed spectral points for HC (n=100) & patients with AD (n=250) (B) PCA scores plot for HC & AD (C) PLS-DA discriminant function graph for classification of HC & AD using cross validation (D) Average pre-processed spectral points for HC (n=100) & DR (n=380) (E) PCA scores plot for HC & DR (F) PLS-DA discriminant function graph for classification of HC & DR using cross validation



Figure S3: ATR-FTIR spectral classification of control groups (CG) vs. active disease (AD) & control groups (CG) vs. disease remission (DR) for plasma samples. CG included healthy controls and disease controls of membranous nephropathy, minimal change disease, immunoglobulin A nephropathy and acute kidney injury with infection. The DR cohort consisted of those in disease remission at the time of enrolment (n=38) in addition to those who achieved disease remission post enrolment following successful remission induction therapy (n=14) – (A) Average pre-processed spectral points for CG (n=450) & patients with AD (n=250) (B) PLS-DA discriminant function graph for classification of CG & AD using cross validation (C) PLS-DA coefficients for identification of main band differences for CG vs. AD (D) Average pre-processed spectral points for CG (n=450) & patients with DR (n=520) (E) PLS-DA discriminant function graph for classification of CG & DR using cross validation (F) PLS-DA coefficients for identification of main band differences for CG vs. DR



Figure S4: PCA scores plot of prednisolone use (n=14) vs. no prednisolone (n=11) use amongst the active disease cohort



Figure S5: PCA scores plot of > 5mg/day prednisolone use (n=15) vs. no prednisolone use (n=23) amongst the disease remission cohort



Figure S6: PCA scores plot of Rituximab exposure (n=13) vs. no Rituximab exposure (n=25) in the preceding 6 months amongst the disease remission cohort



Figure S7: ATR-FTIR spectral classification of active disease vs. disease remission for serum samples - (A) Raw spectral data (B) Pre-processed spectra (C) PCA scores plot (D) PLS-DA discriminant function graph (E) ROC curve for PLS-DA (F) PLS-DA coefficients for identification of spectral biomarkers



Figure S8: ATR-FTIR spectral classification of active disease vs. paired remission for serum samples following successful remission induction therapy - (A) Raw spectral data (B) Pre-processed spectra (C) PCA scores plot (D) PLS-DA discriminant function graph (E) ROC curve for PLS-DA (F) PLS-DA coefficients for identification of spectral biomarkers



Figure S9: ATR-FTIR spectral classification of healthy controls (HC) vs. active disease (AD) & healthy controls (HC) vs. disease remission (DR) for serum samples – (A) Average pre-processed spectral points for HC (n=100) & patients with AD (n=250) (B) PCA scores plot for HC & AD (C) PLS-DA discriminant function graph for classification of HC & AD using cross validation (D) Average pre-processed spectral points for HC (n=100) & DR (n=380) (E) PCA scores plot for HC & DR (F) PLS-DA discriminant function graph for classification of HC & DR (F) PLS-DA discriminant function graph for classification of HC & DR (F) PLS-DA discriminant function graph for classification of HC & DR (F) PLS-DA discriminant function graph for classification of HC & DR using cross validation



Figure S10: Main band differences for healthy controls (HC) vs. active disease (AD) using PCA loadings on PC2 from serum samples - 1504 cm⁻¹ (higher in HC, Amide II).



Figure S11: ATR-FTIR spectral classification of active disease vs. disease remission for urine samples - (A) Raw spectral data (B) Pre-processed spectra (C) PCA scores plot (D) PLS-DA discriminant function graph (E) ROC curve for PLS-DA (F) PLS-DA coefficients for identification of spectral biomarkers



Figure S12: ATR-FTIR spectral classification of active disease vs. paired remission for urine samples following successful remission induction therapy - (A) Raw spectral data (B) Pre-processed spectra (C) PCA scores plot (D) PLS-DA discriminant function graph (E) ROC curve for PLS-DA (F) PLS-DA coefficients for identification of spectral biomarkers



Figure S13: ATR-FTIR spectral classification of healthy controls (HC) vs. active disease (AD) & healthy controls (HC) vs. disease remission (DR) for urine samples – (A) Average pre-processed spectral points for HC (n=100) & patients with AD (n=220) (B) PCA scores plot for HC & AD (C) PLS-DA discriminant function graph for classification of HC & AD using cross validation (D) Average pre-processed spectral points for HC (n=100) & DR (n=320) (E) PCA scores plot for HC & DR (F) PLS-DA discriminant function graph for classification of HC & DR using cross validation



Figure S14: Main band differences for healthy controls (HC) vs. active disease (AD) using PCA loadings on PC2 from urine samples - 1710 cm⁻¹ (higher in HC, C=O thymine), 1612 cm⁻¹ (higher in HC, adenine vibration in DNA), 1540 cm⁻¹ (higher in AD, protein amide II absorption β -sheet), 1445 cm⁻¹ (higher in HC, δ (CH2) in lipids or fatty acids), 1390 cm⁻¹ (higher in AD, CH3 bending), 1170 cm⁻¹ (higher in HC, v_{as} (CO-O-C)), 1035 cm⁻¹ (higher in AD, skeletal *trans* v(C-C) of DNA).



Figure S15: Power test based on a Fisher's exact test (two-tails, error probability = 0.05) showing the power varying the total sample size of active and remission cases.

Table S1: Characteristics of disease control groups at the time of enrolment & sample collection					
	MM (n=10)	MCD (n=5)	lgA (n=10)	AKI (n=10)	
Mean Age (SD)	63 <u>+</u> 9.4	50 <u>+</u> 21.9	48 <u>+</u> 12.9	71 <u>+</u> 8.7	
Sex					
Male	8	2	8	6	
Female	2	3	2	4	
Median serum creatinine (µmol/L)	103 (181-84)	81 (137-72)	212 (258-109)	330 (365-285)	
Median eGFR (mls/min/1.73m ²)	59 (60-32)	90 (90-35)	27 (74-22)	13 (14-12)	
Other Laboratory Salient Laboratory Results:					
Mean Haemoglobin (g/L)	121 <u>+</u> 12.9	133 <u>+</u> 14.2	128 <u>+</u> 17.9	93 <u>+</u> 13	
Mean White cell count (10 ⁹ /L)	6 <u>+</u> 2.2	9 <u>+</u> 4.2	7 <u>+</u> 2.4	8 <u>+</u> 4.2	
Mean Lymphocyte count (10 ⁹ /L)	1.7 <u>+</u> 0.6	1.8 <u>+</u> 0.6	1.7 <u>+</u> 0.5	0.9 <u>+</u> 0.5	
Mean Neutrophil count (10º/L)	4 <u>+</u> 1.6	6 <u>+</u> 4.3	5 <u>+</u> 2.2	6 <u>+</u> 3.8	
Mean Platelet count (10 ⁹ /L)	258 <u>+</u> 84.7	291 <u>+</u> 13.7	260 <u>+</u> 49.7	253 <u>+</u> 95	
Median CRP (mg/L)	*	*	*	83 (122-47)	

MM, Membranous Nephropathy; MCD, Minimal Change Disease; IgA, Immunoglobulin A Nephropathy; AKI, Acute Kidney Injury

	Accuracy (%)	Sensitivity (%)	Specificity (%)	F-Score (%)
HC vs. AD				
Training (4 LVs)	94.0	88.0	100	93.6
Cross-validation	82.0	84.0	80.0	82.0
HC vs. DR				
Training (3 LVs)	92.3	94.7	90.0	92.3
Cross-validation	81.0	92.1	70.0	79.5

Table S3: Classification parameters for plasma samples for control groups (CG) vs. active disease (AD) and all disease remission (DR)						
	Accuracy (%)	Sensitivity (%)	Specificity (%)	F-Score (%)		
CG vs. AD						
Training (7 LVs)	100	100	100	100		
Cross-validation	93	93	92	92		
Test	89	80	94	86		
CG vs. DR						
Training (9 LVs)	98	97	100	98		
Cross-validation	86	87	85	86		
Test	84	86	82	84		

Table S4: Comparative analysis between clinical variables and ATR-FTIR spectral data from plasma samples						
Disease Remission	Sensitivity of	Specificity of	Coefficients of			
	clinical variable	clinical variable	determination (R ²)			
Age	-	-	0.03			
Gender	0.55	0.61	0			
ANCA Serotype						
MPO	0.61	0.2	0.06			
PR3	0.21	0.8	0.02			
Negative	0.67	0.53	0.01			
ANCA titre	-	-	0.05			
Serum creatinine (µmol/L)	-	-	0.43			
eGFR(mls/min/1.73m ²)	-	-	0.3			
Haemoglobin	-	-	0.26			
White cell count	-	-	0.01			
Lymphocyte count	-	-	0			
Neutrophil count	-	-	0			
Platelet count	-	-	0.01			
CRP	-	-	0			
ESR	-	-	0.16			
Serum albumin	-	-	0.1			
Total Protein	-	-	0.45			

Table S5: Classification parameters for serum samples in active disease (AD) vs. disease remission (DR)						
AD vs. DR	Accuracy (%)	Sensitivity (%)	Specificity (%)	F-Score (%)		
Training (4 LVs)	91.2	95.7	86.7	91.0		
Cross-validation	91.2	95.7	86.7	91.0		
Test	88.3	86.7	90.0	88.3		

Table S6: Classification parameters for serum samples in active disease (AD) vs. paired remission (PR)						
AD vs. PR Accuracy (%) Sensitivity (%) Specificity (%) F-Score (%)						
Training (2 LVs)	95.0	100	90.0	94.7		
Cross-validation	95.0	100	90.0	94.7		
Test	92.8	85.7	100	92.3		

Table S7: Comparative analysis between clinical variables and ATR-FTIR spectral data from serum samples					
Active disease	Sensitivity of	Specificity of	Coefficients of		
	clinical variable	clinical variable	determination (R ²)		
Age	-	-	0.15		
Gender	0.75	0.69	0.24		
BVAS	-	-	0.13		
Organ involvement:					
Constitutional signs or symptoms	0.75	0.40	0.24		
Mucous Membrane / Ophthalmic	0.50	0.58	0.00		
Cutaneous	0.92	1.00	0.02		
ENT	0.33	0.31	0.23		
Respiratory	0.83	0.63	0.03		
Cardiovascular	1.00	1.00	0.01		
Renal	1.00	1.00	0.54		
Neurological	0.40	0.65	0.00		
ANCA Positivity	0.91	0.75	0.22		
ANCA Serotype					
MPO	0.33	0.81	0.00		
PR3	0.75	0.54	0,00		
Negative	0.75	0.86	0.22		
ANCA titre	-	-	0.06		
Serum creatinine (µmol/L)	-	-	0.28		
eGFR(mls/min/1.73m ²)	-	-	0.44		
Haemoglobin	-	-	0.54		
White cell count	-	-	0.01		
Lymphocyte count	-	-	0.21		
Neutrophil count	-	-	0.04		
Platelet count	-	-	0.15		
CRP	-	-	0.28		
ESR	-	-	0.00		

ENT, ear nose and throat; ANCA, anti-neutrophil cytoplasmic autoantibody; MPO, myeloperoxidase; PR3, proteinase-3; BVAS, Birmingham vasculitis activity score; eGFR, estimated glomerular filtration rate; ESR, erythrocyte sedimentary rate; CRP, C-reactive protein

	Accuracy (%)	Sensitivity (%)	Specificity (%)	F-Score (%)
HC vs. AD				
Training (3 LVs)	100	100	100	100
Cross-validation	89.0	88.0	90.0	89.0
HC vs. DR				
Training (3 LVs)	98.7	97.4	100	98.7
Cross-validation	97.3	94.7	100	97.3

Table S9: Potential spectral biomarkers for distinguishing active disease and disease remission using serum samples				
Wavenumber (cm ⁻¹)	Tentative assignment	Influence on Active AAV		
1716	v(C=O) DNA/RNA	\uparrow		
1704	v(C=O) thymine	\uparrow		
1662	Amide I	\downarrow		
1623	Base carbonyl stretching and ring breathing mode of nucleic acids	\uparrow		
1558	Ring base	\uparrow		
1543	Amide II	\uparrow		
1495	ν(C=C), δ(C-H)	\downarrow		
1701	C=O guanine	\uparrow		
1646	Amide I	\checkmark		
1558	Ring base mode	\uparrow		
1500	Amide II	\downarrow		
1407	CH3 asymmetric deformation	\wedge		

Table S10: Classification parameters for urine samples in active disease (AD) vs. disease remission (DR)						
AD vs. DR	Accuracy (%)	Sensitivity (%)	Specificity (%)	F-Score (%)		
Training (7 LVs)	100	100	100	100		
Cross-validation	82.3	78.9	85.7	82.2		
Test	72.1	69.2	75.0	72.0		

Table S11: Classification parameters for urine samples in active disease (AD) vs. paired remission (PR)							
AD vs. PR	Accuracy (%)	Sensitivity (%)	Specificity (%)	F-Score (%)			
Training (2 LVs)	100	100	100	100			
Cross-validation	75.7	62.5	88.9	73.4			
Test	65.0	50.0	80.0	61.5			

Table S12: Comparative analysis between clinical variables and ATR-FTIR spectral data from urine samples							
Active disease	Sensitivity of	Specificity of clinical variable	Coefficients of determination (B ²)				
Age	-	-	0.01				
Gender	07	03	0.00				
BVAS	-	-	0.17				
Organ involvement:			0.17				
Constitutional signs or symptoms	0.2	0.6	0.10				
Mucous Membrane / Ophthalmic	0.4	0.4	0.03				
Cutaneous	0.8	1.0	0.05				
ENT	0.6	0.7	0.12				
Respiratory	0.3	0.8	0.00				
Cardiovascular	1.0	0.9	0.00				
Renal	0.7	0.4	0.01				
Neurological	0.2	0.9	0.01				
ANCA Positivity	0.7	0.6	0.05				
ANCA Serotype							
MPO	0.5	0.9	0.15				
PR3	0.9	0.3	0.01				
Negative	0.6	0.6	0.04				
ANCA titre	-	-	0.05				
Serum creatinine (umol/L)	-	-	0.02				
$\alpha \in EP(m s/min/1, 73m^2)$			0.03				
	-	-	0.02				
Haemoglobin	-	-	0.00				
White cell count	-	-	0.24				
Lymphocyte count	-	-	0.00				
Neutrophil count	-	-	0.32				
Platelet count	-	-	0.06				
CRP	-	-	0.41				
ESR	-	-	0.24				
uPCR	-	-	0.46				
Urine white cell count	-	-	0.01				
Bacterial growth							
No growth (n=19)	0.8	0.0	0.01				
<i>Streptococcus agalactiae</i> (n=1)	1.0	0.9	0.00				
Enterococcus faecalis (n=1)	1.0	0.9	0.01				
Mixed growth (n=1)	1.0	0.9	0.00				

ENT, ear nose and throat; ANCA, anti-neutrophil cytoplasmic autoantibody; MPO, myeloperoxidase; PR3, proteinase-3; BVAS, Birmingham vasculitis activity score; eGFR, estimated glomerular filtration rate; ESR, erythrocyte sedimentary rate; CRP, C-reactive protein; uPCR, urine protein creatinine ratio; bacterial growth n=3

able S13: Classification parameters for urine samples in healthy controls (HC) vs. active disease (AD) and disease remission (DR)						
	Accuracy (%)	Sensitivity (%)	Specificity (%)	F-Score (%)		
HC vs. AD						
Training (3 LVs)	92.7	95.5	90.0	92.7		
Cross-validation	85.4	90.9	80.0	85.1		
HC vs. DR						
Training (1 LVs)	84.0	78.1	90.0	83.6		
Cross-validation	85.6	81.3	90.0	85.4		

Table S14: Potential spectral biomarkers for distinguishing active disease and disease remission using urine samples based on the PLS-					
DA coefficients (v = stretching; δ = bending)					
Wavenumber (cm ⁻¹)	Tentative assignment	Influence on Active AAV			
1728	v(C=O)	\uparrow			
1680	Amide I	\uparrow			
1632	v(C=C) uracil	\uparrow			
1512	In-plane δ (CH) phenyl ring	\uparrow			
1470	δ (CH ₂) methylene chains in lipids	\uparrow			
1415	δ(C-H), δ(NH), ν(C-N)	\uparrow			
1380	$\delta(CH_3)$	\checkmark			
1339	Collagen	\checkmark			
1164	v(C-O) of C-OH groups of serine, threosine and tyrosine of proteins	\checkmark			
1020	DNA	\uparrow			
984	OCH₃ polysaccharides	\checkmark			
1689	Base carbonyl stretching and ring breathing mode of nucleic acids	\checkmark			
1647	Amide I	\uparrow			
1546	Amide II of proteins	\uparrow			
1512	In-plane CH bending from phenyl rings	\uparrow			
1460	$\delta_{ m as}({ m CH}_3)$ collagen	\checkmark			
1155	C-O stretching	\checkmark			